Outlook Therapeutics, Inc. (OTLK)
0.6405
-0.03
(-3.90%)
USD |
NASDAQ |
Sep 08, 16:00
0.6447
0.00 (0.00%)
Pre-Market: 08:05
Outlook Therapeutics Debt to Equity Ratio : -1.774 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.774 |
| March 31, 2026 | -0.9377 |
| December 31, 2025 | -0.957 |
| June 30, 2025 | -0.933 |
| March 31, 2025 | -1.026 |
| December 31, 2024 | -0.617 |
| September 30, 2024 | -0.4069 |
| June 30, 2024 | -0.3911 |
| March 31, 2024 | -0.3333 |
| December 31, 2023 | -1.501 |
| September 30, 2023 | -2.463 |
| June 30, 2023 | -6.313 |
| March 31, 2023 | 3.036 |
| December 31, 2022 | 2.021 |
| September 30, 2022 | 1.254 |
| June 30, 2022 | 0.5238 |
| March 31, 2022 | 0.6356 |
| December 31, 2021 | 0.4591 |
| September 30, 2021 | 2.583 |
| June 30, 2021 | 0.916 |
| March 31, 2021 | 0.5506 |
| Date | Value |
|---|---|
| December 31, 2020 | -1.078 |
| September 30, 2020 | 1.708 |
| June 30, 2020 | 0.4469 |
| March 31, 2020 | -0.7086 |
| December 31, 2019 | -0.5744 |
| September 30, 2019 | -1.388 |
| June 30, 2019 | -11.03 |
| March 31, 2019 | -0.6927 |
| December 31, 2018 | -0.8178 |
| September 30, 2018 | -1.054 |
| June 30, 2018 | -2.359 |
| March 31, 2018 | -1.422 |
| December 31, 2017 | -2.180 |
| September 30, 2017 | -0.5994 |
| June 30, 2017 | -0.5869 |
| March 31, 2017 | -0.4603 |
| December 31, 2016 | -0.5027 |
| September 30, 2016 | -1.679 |
| June 30, 2016 | 5.909 |
| March 31, 2016 | -0.7171 |
| December 31, 2015 | -0.501 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Valion Bio, Inc. | 1.465 |
| Agenus, Inc. | -1.458 |
| Amgen, Inc. | 4.903 |
| Anika Therapeutics, Inc. | 0.1839 |
| BioCryst Pharmaceuticals, Inc. | -1.842 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 26.18M |
| Total Liabilities (Quarterly) | 36.58M |
| Shareholders Equity (Quarterly) | -10.39M |
| Current Ratio | 0.8078 |
| Net Debt Paydown Yield | 0.85% |